Axoltis Pharma is focused on developing innovative therapeutic peptides aimed at treating neurodegenerative diseases and traumatic neurological disorders. Their primary candidate, SCO-spondin, is a multifunctional glycoprotein produced by the human subcommissural organ, which plays a crucial role in neurogenesis during embryonic development. This protein is characterized by its thrombospondin type 1 repeats (TSRs), which are essential for various developmental processes, including neuronal survival, neurite extension, and neuronal aggregation. The research conducted by A. Meiniel and S. Gobron highlights the significance of these TSR motifs, particularly the NX210c peptide, in facilitating neuron/glia interactions and promoting overall neuronal health.

The technologies developed by Axoltis Pharma center around the properties of the NX210c peptide, which has been shown to provide neuroprotection, enhance synaptic transmission, and improve blood-brain barrier integrity. These properties are critical for addressing a wide range of neuropathologies, as they contribute to reducing permeability and promoting the expression of tight junctions within the blood-brain barrier. By leveraging the unique characteristics of SCO-spondin and its associated peptides, Axoltis Pharma aims to create first-in-class drugs that significantly improve the functionality and quality of life for patients suffering from neurological disorders with high unmet medical needs.

France

Axoltis pharma is a biopharmaceutical company dedicated to develop a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs.

Our innovative approach: combining Preventative, Neuroprotective, Regenerative & Remodeling properties in a single drug, as the key to cure complex neurological disorders. 

Our products are first-in-class multifunctional peptides with high potential in many CNS disorders.

Axoltis Pharma

Company Details